Condition
Sebaceous Hyperplasia
Total Trials
5
Recruiting
1
Active
1
Completed
2
Success Rate
66.7%-20% vs avg
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
Termination Rate
20.0%
1 terminated out of 5 trials
Success Rate
66.7%
-19.8% vs benchmark
Late-Stage Pipeline
20%
1 trials in Phase 3/4
Results Transparency
100%
2 of 2 completed with results
Key Signals
2 with results67% success
Data Visualizations
Phase Distribution
5Total
Not Applicable (3)
P 2 (1)
P 4 (1)
Trial Status
Completed2
Recruiting1
Terminated1
Not Yet Recruiting1
Trial Success Rate
66.7%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT04429607Phase 2Not Yet RecruitingPrimary
Treatment of Sebaceous Hyperplasia With PDL and Nd:YAG Versus Erbium:YAG: A Randomized Controlled Trial
NCT06840470Phase 4RecruitingPrimary
Investigating the Effect of Topical Imiquimod on Sebaceous Hyperplasia
NCT04539886Not ApplicableCompleted
Comparative Study Between CellFX and Electrodessication in Sebaceous Hyperplasia (SH) Lesions
NCT03612570Not ApplicableCompleted
Nano-Pulse Stimulation (NPS) in Sebaceous Hyperplasia
NCT04253418Not ApplicableTerminatedPrimary
Nano-Pulse Stimulation (NPS) in Sebaceous Hyperplasia Optimization Study
Showing all 5 trials